Dermata Therapeutics, Inc.
DRMA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001853816
No open-market purchases or sales by Dermata Therapeutics, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $158.0K in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Dermata Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 8 | 11 | +3 |
| Shares | 72.7K | 853.9K | +781.3K (+1,074.8%) |
| Value | $91.0K | $554.0K | +$463.0K (+508.8%) |
New holders (6)
Institutions that held Dermata Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 637,147 | $414.0K | 0.01% |
| Citadel Advisors LLC | 79,969 | $52.0K | 0.00% |
| Citigroup Inc | 48,942 | $32.0K | 0.00% |
| Sage Capital Advisors,llc | 12,000 | $8.00K | 0.00% |
| Susquehanna International Group, LLP | 11,496 | $7.00K | 0.00% |
| Total Clarity Wealth Management, Inc. | 500 | $0 | 0.00% |
Sold out (3)
Institutions that held Dermata Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| BlackRock Inc. | 17,669 | $22.0K |
| JPMorgan Chase & Co | 569 | $1.00K |
| Morgan Stanley | 3 | $0 |